BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta AK, Kumar GK, Rani K, Pokhriyal R, Khan MI, Kumar DR, Goyal V, Tripathi M, Gupta R, Chadda RK, Vanamail P, Mohanty AK, Hariprasad G. 2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson's disease and schizophrenia. Neuropsychiatr Dis Treat 2019;15:1031-44. [PMID: 31114209 DOI: 10.2147/NDT.S198559] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Patel S, Sharma D, Uniyal A, Akhilesh, Gadepalli A, Tiwari V. Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside. Metab Brain Dis 2022. [PMID: 35239143 DOI: 10.1007/s11011-022-00926-5] [Reference Citation Analysis]
2 Gupta AK, Pokhriyal R, Khan MI, Kumar DR, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G. Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson's Disease And Schizophrenia. Neuropsychiatr Dis Treat 2019;15:2853-67. [PMID: 31632033 DOI: 10.2147/NDT.S214217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gupta AK, Pokhriyal R, Das U, Khan MI, Ratna Kumar D, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G. Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia. Neuropsychiatr Dis Treat 2019;15:2073-85. [PMID: 31410011 DOI: 10.2147/NDT.S205550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]